Literature DB >> 25063191

Plasma 8-hydroxy-2'-deoxyguanosine Levels in Huntington Disease and Healthy Controls Treated with Coenzyme Q10.

K M Biglan1, E R Dorsey2, R V V Evans3, C A Ross4, S Hersch5, I Shoulson6, W Matson7, K Kieburtz3.   

Abstract

We analyzed plasma 8OHdG concentrations in 20 individuals enrolled in the Pre-2CARE study before and after treatment with CoQ. Treatment resulted in a mean reduction in 8OHdG of 2.9 ± 2.9 pg/ml for the cohort (p = 0.0003) and 3.0 ± 2.6 pg/ml, for the HD group (p = 0.002). Baseline 8OHdG levels were not different between individuals with HD and controls (19.3 ± 3.2 pg/ml vs. 19.5 ± 4.7 pg/ml, p = 0.87) though baseline CoQ levels were elevated in HD compared with controls (p < 0.001). CoQ treatment reduces plasma 8OHdG and this reduction may serve as a marker of pharmacologic activity of CoQ in HD.

Entities:  

Keywords:  8OHdG; Huntington disease; coenzyme Q10; oxidative injury

Mesh：

Substances：

Year:  2012        PMID： 25063191      PMCID： PMC4115297          DOI： 10.3233/JHD-2012-120007

Source DB:  PubMed          Journal:  J Huntingtons Dis        ISSN： 1879-6397


  16 in total

1.  Oxidative stress in patients with Friedreich ataxia.

Authors:  J B Schulz; T Dehmer; L Schöls; H Mende; C Hardt; M Vorgerd; K Bürk; W Matson; J Dichgans; M F Beal; M B Bogdanov
Journal:  Neurology       Date:  2000-12-12       Impact factor: 9.910

2.  Increased oxidative damage to DNA in ALS patients.

Authors:  M Bogdanov; R H Brown; W Matson; R Smart; D Hayden; H O'Donnell; M Flint Beal; M Cudkowicz
Journal:  Free Radic Biol Med       Date:  2000-10-01       Impact factor: 7.376

3.  Study on safety and bioavailability of ubiquinol (Kaneka QH) after single and 4-week multiple oral administration to healthy volunteers.

Authors:  Kazunori Hosoe; Mitsuaki Kitano; Hideyuki Kishida; Hiroshi Kubo; Kenji Fujii; Mikio Kitahara
Journal:  Regul Toxicol Pharmacol       Date:  2006-08-21       Impact factor: 3.271

4.  Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG.

Authors:  S M Hersch; S Gevorkian; K Marder; C Moskowitz; A Feigin; M Cox; P Como; C Zimmerman; M Lin; L Zhang; A M Ulug; M F Beal; W Matson; M Bogdanov; E Ebbel; A Zaleta; Y Kaneko; B Jenkins; N Hevelone; H Zhang; H Yu; D Schoenfeld; R Ferrante; H D Rosas
Journal:  Neurology       Date:  2006-01-24       Impact factor: 9.910

5.  Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease.

Authors:  Robert J Ferrante; Ole A Andreassen; Alpaslan Dedeoglu; Kimberly L Ferrante; Bruce G Jenkins; Steven M Hersch; M Flint Beal
Journal:  J Neurosci       Date:  2002-03-01       Impact factor: 6.167

6.  Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice.

Authors:  Karen M Smith; Samantha Matson; Wayne R Matson; Kerry Cormier; Steven J Del Signore; Sean W Hagerty; Edward C Stack; Hoon Ryu; Robert J Ferrante
Journal:  Biochim Biophys Acta       Date:  2006-04-17

7.  At risk for Huntington disease: The PHAROS (Prospective Huntington At Risk Observational Study) cohort enrolled.

Authors: 
Journal:  Arch Neurol       Date:  2006-07

8.  Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline.

Authors:  Clifford W Shults; David Oakes; Karl Kieburtz; M Flint Beal; Richard Haas; Sandy Plumb; Jorge L Juncos; John Nutt; Ira Shoulson; Julie Carter; Katie Kompoliti; Joel S Perlmutter; Stephen Reich; Matthew Stern; Ray L Watts; Roger Kurlan; Eric Molho; Madaline Harrison; Mark Lew
Journal:  Arch Neurol       Date:  2002-10

9.  A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease.

Authors: 
Journal:  Neurology       Date:  2001-08-14       Impact factor: 9.910

10.  Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects.

Authors:  H Christopher Hyson; Karl Kieburtz; Ira Shoulson; Michael McDermott; Bernard Ravina; Elisabeth A de Blieck; Merit E Cudkowicz; Robert J Ferrante; Peter Como; Sam Frank; Carol Zimmerman; Merit E Cudkowicz; Kimberly Ferrante; Kristyn Newhall; Danna Jennings; Tammie Kelsey; Francis Walker; Vicki Hunt; Susan Daigneault; Michele Goldstein; Joseph Weber; Arthur Watts; M Flint Beal; Susan E Browne; Linda J Metakis
Journal:  Mov Disord       Date:  2010-09-15       Impact factor: 10.338
View more
  2 in total

Review 1.  What, When and How to Measure-Peripheral Biomarkers in Therapy of Huntington's Disease.

Authors:  Lukasz Przybyl; Magdalena Wozna-Wysocka; Emilia Kozlowska; Agnieszka Fiszer
Journal:  Int J Mol Sci       Date:  2021-02-04       Impact factor: 5.923

2.  8OHdG is not a biomarker for Huntington disease state or progression.

Authors:  Beth Borowsky; John Warner; Blair R Leavitt; Sarah J Tabrizi; Raymund A C Roos; Alexandra Durr; Chris Becker; Cristina Sampaio; Allan J Tobin; Howard Schulman
Journal:  Neurology       Date:  2013-04-24       Impact factor: 9.910
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.